BSTG:OTC-Biostage, Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 1.35

Change

0.00 (0.00)%

Market Cap

USD 0.01B

Volume

2.42K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-0.41 (-0.59%)

USD156.28B 27.99 2.61
CSLLY CSL Limited

-0.18 (-0.16%)

USD99.45B 47.90 27.53
CMXHF CSL Limited

N/A

USD93.11B 46.52 27.53
GNMSF Genmab A/S

+2.25 (+0.58%)

USD25.24B 107.84 2.61
UCBJY UCB SA

N/A

USD20.22B 19.89 17.71
UCBJF UCB SA

N/A

USD19.85B 20.71 17.56
SBMFF Sino Biopharmaceutical Limited

N/A

USD16.91B 27.58 3.18
SBHMY Sino Biopharmaceutical Limited

N/A

USD16.74B 31.68 3.18
PPTDF PeptiDream Inc

N/A

USD6.63B 260.99 1.62
IDRSF Idorsia Ltd

N/A

USD4.62B 130.60 N/A

ETFs Containing BSTG

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -32.84% 22% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.84% 22% F 21% F
Trailing 12 Months  
Capital Gain -38.64% 19% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.64% 19% F 17% F
Trailing 5 Years  
Capital Gain -38.64% 57% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.64% 56% F 31% F
Average Annual (5 Year Horizon)  
Capital Gain 318.37% N/A N/A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 318.37% N/A N/A 93% A
Risk Return Profile  
Volatility (Standard Deviation) 856.40% N/A N/A 8% F
Risk Adjusted Return 37.18% N/A N/A 72% C-
Market Capitalization 0.01B 46% F 37% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.36 49% F 20% F
Price / Cash Flow Ratio -2.09 45% F 70% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -347.94% 13% F 4% F
Return on Invested Capital -579.74% 6% F 2% F
Return on Assets -144.84% 25% F 8% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.35 21% F 23% F
Short Percent 6.77% 13% F 26% F
Beta 0.20 73% C 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.